Literature DB >> 6272836

1 Alpha-25,26-trihydroxyvitamin D3: an in vivo and in vitro metabolite of vitamin D3.

T A Reinhardt, J L Napoli, B Praminik, E T Littledike, D C Beitz, J J Partridge, M R Uskoković, R L Horst.   

Abstract

A new metabolite of vitamin D3 has been isolated from the plasma of vitamin D3 treated cows and has been generated from 25(S),26-dihydroxyvitamin D3 with homogenates of vitamin D deficient chick kidney. This metabolite has been identified as 1,25,26-trihydroxyvitamin D3 by comigration with synthetic 1,25(S),26-trihydroxyvitamin D3 in four chromatographic systems, ultraviolet spectroscopy, mass spectrometry, and high-pressure liquid chromatography and mass spectrometry of derivatives. 1,25(S),26-Trihydroxyvitamin D3 is one-tenth as effective as 1,25-dihydroxyvitamin D3 in binding to the chick intestinal cytosol 1,25-dihydroxyvitamin D receptor. Either 25(S),26-dihydroxyvitamin D3 or 1,25-dihydroxyvitamin D3 can serve as precursor for in vitro production of 1,25,26-trihydroxyvitamin D3 by chick kidney tissue.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6272836     DOI: 10.1021/bi00524a050

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  3 in total

1.  Production of C-24- and C-23-oxidized metabolites of 1,25-dihydroxycholecalciferol by cultured kidney cells (LLC PK1) and their presence in kidney in vivo.

Authors:  J L Napoli; C A Martin
Journal:  Biochem J       Date:  1984-05-01       Impact factor: 3.857

2.  Vitamin D status in Crohn's disease: association with nutrition and disease activity.

Authors:  A D Harries; R Brown; R V Heatley; L A Williams; S Woodhead; J Rhodes
Journal:  Gut       Date:  1985-11       Impact factor: 23.059

3.  1α,25(OH)2-3-epi-vitamin D3, a natural physiological metabolite of vitamin D3: its synthesis, biological activity and crystal structure with its receptor.

Authors:  Ferdinand Molnár; Rita Sigüeiro; Yoshiteru Sato; Clarisse Araujo; Inge Schuster; Pierre Antony; Jean Peluso; Christian Muller; Antonio Mouriño; Dino Moras; Natacha Rochel
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.